Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06359600
Other study ID # HS-10501-101
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date March 14, 2024
Est. completion date June 30, 2025

Study information

Verified date April 2024
Source Jiangsu Hansoh Pharmaceutical Co., Ltd.
Contact Wei Hu, MD
Phone (+86)13856086475
Email ayefygcp@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety, tolerability, Pharmacokinetics and Pharmacodynamics of single dose and multiple dose of HS-10501 tables in healthy subjects. This is the first clinical study of HS-10501 tables. This study has 2 parts. Parts A involve a single dose of HS-10501 tables or placebo and will last about 8 days. Also, this part will also further explore the food effect. Parts B involve multiple doses of HS-10501 tables or placebo and will last about 4 weeks.


Recruitment information / eligibility

Status Recruiting
Enrollment 84
Est. completion date June 30, 2025
Est. primary completion date January 31, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: 1. Able and willing to provide written informed consent and to comply with the study protocol; 2. Must be 18 to 55 years of age (inclusive) healthy male or female; 3. Body weight of at least 50.0 kg for male, and 45.0 kg for female; and Body Mass Index (BMI) within the range of 19.0 to 28.0 kg/m2 (inclusive); 4. Subjects (including partners) of childbearing potential are willing to use protocol specified effective methods of contraception from the date of signing the informed consent form to 30 days after the last dose; 5. Female subjects must have a negative blood pregnancy test report 3 days before dosing. Exclusion Criteria: 1. Pregnant or lactating women; 2. Subjects with a history of cardiovascular, respiratory, liver, kidney, digestive tract, mental, neurological, hematological, immune, and metabolic abnormalities and other diseases, and not suitable for the study as assessed by the investigator; 3. Subjects with clinically significant abnormalities in vital signs, physical examination, laboratory tests, or 12-lead ECG during the screening period; 4. Have received major surgery within 3 months before screening or have surgery plan during the study; 5. History of severe infection within 30 days before screening or currently experiencing severe infection; 6. The alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) are higher than the upper limit of normal (ULN); 7. Positive for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV-Ab), HIV antibody (HIV-Ab), or treponema pallidum antibody (TP-Ab); 8. Glycosylated hemoglobin (HbA1c) = 6.0% and fasting blood glucose = 3.9 mmol/L (70 mg/dL) or = 6.1 mmol/L (110 mg/dL) at screening; 9. History of drug abuse and use of hard drugs within 1 year before the study or positive for urine drug screening; 10. Addicted to smoking or smokers who smoke 5 or more cigarettes per day on average within 3 months before screening; 11. History of alcohol abuse, or a single consumption of more than 14 units of alcohol in the past two weeks, or positive for breath alcohol test at screening; 12. Participating in any clinical trial involving drugs or medical devices within 3 months before screening; 13. Blood donation or loss of = 400 mL or blood transfusion within 3 months before screening; blood donation or loss of = 200 mL within 1 month before screening; 14. Subjects with severe allergic disease, or suspected allergy to any ingredient in the study drugs, or allergic constitution; 15. Subjects with concomitant diseases that may significantly affect the absorption of drugs or nutrients as judged by the investigator; 16. Subjects with a history of pancreatitis, and serum amylase or lipase greater than the ULN; 17. History or family history of medullary thyroid cancer and multiple endocrine neoplasia syndrome type 2; 18. Diet or weight loss treatment within 3 months prior to administration or having weight change of more than 5% or significant change in living habits; 19. Any medication taken within 2 weeks or 5 half-lives (whichever is longer) before screening and any medication expected to be taken throughout the study; 20. Any physiological or psychological diseases or conditions that may increase the risk of the study, affect the subject's compliance with the protocol, or affect the subject's completion of the study, as judged by the investigator; 21. Those who should not be enrolled per the investigator's opinion.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
HS-10501 tablet
Administered orally
Placebo
Administered orally

Locations

Country Name City State
China The second hospital of Anhui University Hefei Anhui

Sponsors (1)

Lead Sponsor Collaborator
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence and severity of adverse events(AE) , serious AEs and AE leading to withdrawal from treatment. An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. A serious AE (SAE) is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; or is a congenital anomaly/birth defect. Day1 to last follow-up, SAD: Baseline to Day 8; MAD: Baseline to Day 35.
Primary Number of participants with clinically significant abnormalities in lab tests Laboratory tests include blood routine, urine routine, blood biochemistry and coagulation function, etc. Day1 to last follow-up, SAD: Baseline to Day 8; MAD: Baseline to Day 35.
Primary Number of participants with clinically significant change from baseline in vital signs Day1 to last follow-up, SAD: Baseline to Day 8; MAD: Baseline to Day 35.
Primary Change from baseline in Electrocardiogram (ECG) ECG parameters including heart rate, PR interval, QRS interval and QTcF, etc. Day1 to last follow-up, SAD: Baseline to Day 8; MAD: Baseline to Day 35.
Secondary Pharmacokinetic (PK) profile of HS-10501 - AUC0-t Area under the concentration-time curve from time zero to the last quantifiable time point t (AUC0-t) pre-dose to 72 hours post-dose
Secondary Pharmacokinetic (PK) profile of HS-10501 - AUC0-8 Area under the plasma concentration-time curve from time zero to infinity (AUC0-8); pre-dose to 72 hours post-dose
Secondary Pharmacokinetic (PK) profile of HS-10501 - Cmax Maximum observed concentration (Cmax) pre-dose to 72 hours post-dose
Secondary Pharmacokinetic (PK) profile of HS-10501 - Tmax Time to maximum observed concentration (Tmax) pre-dose to 72 hours post-dose
Secondary Pharmacokinetic (PK) profile of HS-10501 - t1/2 Terminal elimination half-life (t1/2) pre-dose to 72 hours post-dose
Secondary Pharmacokinetic (PK) profile of HS-10501 - CL/F Apparent clearance (CL/F) pre-dose to 72 hours post-dose
Secondary Pharmacokinetic (PK) profile of HS-10501- Vz/F Apparent volume of distribution (Vz/F) pre-dose to 72 hours post-dose
Secondary Pharmacokinetic (PK) profile of HS-10501-?z elimination rate constant (?z) pre-dose to 72 hours post-dose
Secondary Pharmacokinetic (PK) profile of HS-10501- AUC0-t area under plasma concentration-time curve within a dosing interval pre-dose to 72 hours post-dose
Secondary Pharmacodynamic (PD) profile of doses of HS-10501 - AUC0-t of blood glucose-time curve after oral glucose tolerance test (OGTT) Area under the glucose-time curve from time zero to the last quantifiable time point t (AUC0-t) after oral glucose tolerance test (OGTT) before to 3 hours after the first intake of glucose on Day-1,Day 1 and Day 28
Secondary Pharmacodynamic (PD) profile of doses of HS-10501 - AUC0-t of blood insulin-time curve after oral glucose tolerance test (OGTT) Area under the insulin-time curve from time zero to the last quantifiable time point t (AUC0-t) after oral glucose tolerance test (OGTT) before to 3 hours after the first intake of glucose on Day-1,Day 1 and Day 28
Secondary body weight changes Change in body weight from baseline after treatment from day-1to day 28
See also
  Status Clinical Trial Phase
Completed NCT05483998 - A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants Phase 1
Recruiting NCT02417714 - Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)
Recruiting NCT02235012 - Cognitive Biases Under Ketamine N/A
Completed NCT04418973 - Analysis of Breath Volatile Organic Compounds After Dyspnea Induced in the Healthy Subject. N/A
Completed NCT05088343 - Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects Phase 1
Not yet recruiting NCT06248801 - Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets Phase 1
Terminated NCT04068259 - Single Ascending Dose Study of PBI-4547 in Healthy Subjects Phase 1
Completed NCT03279302 - Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects Phase 1
Not yet recruiting NCT06233162 - Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets Phase 1
Recruiting NCT04159844 - Evaluation of the Stiffness and Pressure Applied on the Lower Leg by a New Compression Bandage on Healthy Subjects N/A
Completed NCT06137911 - Evaluation of Safety, Tolerability & Pharmacokinetics of JYP0061 in Healthy Adults. Phase 1
Completed NCT04849286 - Measurement of HTL0016878 in Cerebrospinal Fluid Phase 1
Not yet recruiting NCT06233227 - Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule Phase 1
Completed NCT04096157 - A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants Phase 1
Completed NCT01200368 - Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants Phase 3
Recruiting NCT05805033 - Peri-Implant Soft Tissue Integration in Humans: Influence of Material N/A
Completed NCT04027803 - Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris® Phase 1
Recruiting NCT03467880 - Multicenter Study of Impulse Oscillometry in Chinese N/A
Completed NCT02903095 - Single Ascending Dose Study of TD-1439 in Healthy Subjects Phase 1
Active, not recruiting NCT02341508 - A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers Phase 1